These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33752142)

  • 1. Evaluation of a booster tuberculosis vaccine containing mycobacterial DNA-binding protein 1 and CpG oligodeoxynucleotide G9.1 using a Guinea pig model that elicits immunity to Bacillus Calmette-Guérin.
    Maeyama JI; Iho S; Suzuki F; Hayashi D; Yamamoto T; Yamazaki T; Goto Y; Ozeki Y; Matsumoto S; Yamamoto S
    Tuberculosis (Edinb); 2021 May; 128():102067. PubMed ID: 33752142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multistage protein subunit vaccine as BCG-booster confers protection against Mycobacterium tuberculosis infection in murine models.
    Chen Z; Zhang Y; Wu J; Xu J; Hu Z; Fan XY
    Int Immunopharmacol; 2024 Sep; 139():112811. PubMed ID: 39068754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant mycobacterial DNA-binding protein 1 with post-translational modifications boosts IFN-gamma production from BCG-vaccinated individuals' blood cells in combination with CpG-DNA.
    Ozeki Y; Yokoyama A; Nishiyama A; Yoshida Y; Ohara Y; Mashima T; Tomiyama C; Shaban AK; Takeishi A; Osada-Oka M; Yamaguchi T; Tateishi Y; Maeyama JI; Hakamata M; Moro H; Kikuchi T; Hayashi D; Suzuki F; Yamamoto T; Iho S; Katahira M; Yamamoto S; Matsumoto S
    Sci Rep; 2024 Apr; 14(1):9141. PubMed ID: 38644371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA augments antigenicity of mycobacterial DNA-binding protein 1 and confers protection against Mycobacterium tuberculosis infection in mice.
    Matsumoto S; Matsumoto M; Umemori K; Ozeki Y; Furugen M; Tatsuo T; Hirayama Y; Yamamoto S; Yamada T; Kobayashi K
    J Immunol; 2005 Jul; 175(1):441-9. PubMed ID: 15972678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of cattle with a CpG oligodeoxynucleotide-formulated mycobacterial protein vaccine and Mycobacterium bovis BCG induces levels of protection against bovine tuberculosis superior to those induced by vaccination with BCG alone.
    Wedlock DN; Denis M; Skinner MA; Koach J; de Lisle GW; Vordermeier HM; Hewinson RG; van Drunen Littel-van den Hurk S; Babiuk LA; Hecker R; Buddle BM
    Infect Immun; 2005 Jun; 73(6):3540-6. PubMed ID: 15908383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A booster vaccine expressing a latency-associated antigen augments BCG induced immunity and confers enhanced protection against tuberculosis.
    Dey B; Jain R; Gupta UD; Katoch VM; Ramanathan VD; Tyagi AK
    PLoS One; 2011; 6(8):e23360. PubMed ID: 21858087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycobacterium tuberculosis culture filtrate proteins plus CpG Oligodeoxynucleotides confer protection to Mycobacterium bovis BCG-primed mice by inhibiting interleukin-4 secretion.
    da Fonseca DM; Silva CL; Wowk PF; Paula MO; Ramos SG; Horn C; Marchal G; Bonato VL
    Infect Immun; 2009 Dec; 77(12):5311-21. PubMed ID: 19752029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine.
    Gupta N; Garg S; Vedi S; Kunimoto DY; Kumar R; Agrawal B
    Front Immunol; 2018; 9():2371. PubMed ID: 30386336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in infected mice.
    Kohama H; Umemura M; Okamoto Y; Yahagi A; Goga H; Harakuni T; Matsuzaki G; Arakawa T
    Vaccine; 2008 Feb; 26(7):924-32. PubMed ID: 18192091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis.
    Mollenkopf HJ; Grode L; Mattow J; Stein M; Mann P; Knapp B; Ulmer J; Kaufmann SH
    Infect Immun; 2004 Nov; 72(11):6471-9. PubMed ID: 15501778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ag85b/ESAT6-CFP10 adjuvanted with aluminum/poly-IC effectively protects guinea pigs from latent mycobacterium tuberculosis infection.
    Wang C; Lu J; Du W; Wang G; Li X; Shen X; Su C; Yang L; Chen B; Wang J; Xu M
    Vaccine; 2019 Jul; 37(32):4477-4484. PubMed ID: 31266673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant bacille Calmette-Guerin coexpressing Ag85b, CFP10, and interleukin-12 elicits effective protection against Mycobacterium tuberculosis.
    Chen YY; Lin CW; Huang WF; Chang JR; Su IJ; Hsu CH; Cheng HY; Hsu SC; Dou HY
    J Microbiol Immunol Infect; 2017 Feb; 50(1):90-96. PubMed ID: 25732698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of advanced age on Mycobacterium bovis BCG vaccination in guinea pigs aerogenically infected with Mycobacterium tuberculosis.
    Komine-Aizawa S; Yamazaki T; Yamazaki T; Hattori S; Miyamoto Y; Yamamoto N; Haga S; Sugitani M; Honda M; Hayakawa S; Yamamoto S
    Clin Vaccine Immunol; 2010 Oct; 17(10):1500-6. PubMed ID: 20685935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein.
    Deng YH; He HY; Zhang FJ
    Scand J Immunol; 2013 Dec; 78(6):497-506. PubMed ID: 24283772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
    Li Q; Yu H; Zhang Y; Wang B; Jiang W; Da Z; Xian Q; Wang Y; Liu X; Zhu B
    Scand J Immunol; 2011 Jun; 73(6):568-76. PubMed ID: 21323695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycobacterial membrane vesicles administered systemically in mice induce a protective immune response to surface compartments of Mycobacterium tuberculosis.
    Prados-Rosales R; Carreño LJ; Batista-Gonzalez A; Baena A; Venkataswamy MM; Xu J; Yu X; Wallstrom G; Magee DM; LaBaer J; Achkar JM; Jacobs WR; Chan J; Porcelli SA; Casadevall A
    mBio; 2014 Sep; 5(5):e01921-14. PubMed ID: 25271291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenic profiling of Mycobacterium tuberculosis Rv1513 reveals its ability to switch on Th1 based immunity.
    Shi Z; Zhou L; Wang X; Zhang Z; Kong L; Zhang Y
    Arch Microbiol; 2024 Jul; 206(8):352. PubMed ID: 39012499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivated
    Kuczkowska K; Copland A; Øverland L; Mathiesen G; Tran AC; Paul MJ; Eijsink VGH; Reljic R
    Front Immunol; 2019; 10():1588. PubMed ID: 31354727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models.
    Tkachuk AP; Gushchin VA; Potapov VD; Demidenko AV; Lunin VG; Gintsburg AL
    PLoS One; 2017; 12(4):e0176784. PubMed ID: 28453555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs.
    Brandt L; Skeiky YA; Alderson MR; Lobet Y; Dalemans W; Turner OC; Basaraba RJ; Izzo AA; Lasco TM; Chapman PL; Reed SG; Orme IM
    Infect Immun; 2004 Nov; 72(11):6622-32. PubMed ID: 15501795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.